Calidi Biotherapeutics, Inc.
CLDI
$0.415
-$0.016-3.71%
AMEX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 12.90M | 16.55M | 17.45M | 17.20M | 15.98M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 21.78M | 27.57M | 29.57M | 30.33M | 28.99M |
| Operating Income | -21.78M | -27.57M | -29.57M | -30.33M | -28.99M |
| Income Before Tax | -22.20M | -26.28M | -23.23M | -29.96M | -29.20M |
| Income Tax Expenses | 14.00K | 8.00K | 20.00K | 16.00K | 16.00K |
| Earnings from Continuing Operations | -22.21 | -26.29 | -23.25 | -29.98 | -29.22 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 66.00K | 15.00K | -- | -- | -- |
| Net Income | -22.14M | -26.28M | -23.25M | -29.98M | -29.22M |
| EBIT | -21.78M | -27.57M | -29.57M | -30.33M | -28.99M |
| EBITDA | -21.37M | -27.17M | -29.18M | -29.93M | -28.60M |
| EPS Basic | -4.34 | -6.38 | -7.15 | -19.99 | -25.43 |
| Normalized Basic EPS | -2.51 | -3.79 | -4.06 | -12.28 | -15.68 |
| EPS Diluted | -4.34 | -6.38 | -7.15 | -19.99 | -25.43 |
| Normalized Diluted EPS | -2.51 | -3.79 | -4.06 | -12.28 | -15.68 |
| Average Basic Shares Outstanding | 32.00M | 20.27M | 13.88M | 9.43M | 6.74M |
| Average Diluted Shares Outstanding | 32.00M | 20.27M | 13.88M | 9.43M | 6.74M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |